Palladium-Catalyzed Direct C-H trifluoroethylation of aromatic amides**

Manikantha Maraswami, Sreekumar Pankajakshan, Chen Gang, Teck-Peng Loh*

Content

General methods	3
Preparation of starting materials	3-4
Optimization of reaction condition	4-7
General procedure for trifluoroethylation of arenes and the spectral data	7-20
Mechanistic studies	20-22
NMR Spectra	23-78

I. General Methods

Unless otherwise stated, all commercial reagents and solvents were used without additional purification. Analytical thin layer chromatography (TLC) was performed on pre-coated silica gel 60 F254 plates. Visualization on TLC was achieved by the use of UV light (254 nm). Column chromatography was undertaken on silica gel (400-630 mesh) using a proper eluent system. 1H NMR was recorded on Bruker Avance 400 MHz. Chemical shifts were quoted in parts per million (ppm) referenced to the appropriate solvent peak or 0.0 ppm for tetramethylsilane. The following abbreviations were used to describe peak splitting patterns when appropriate: br = broad, s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublet, td = triplet of doublet, ddd = doublet of doublet of doublet, m = multiplet. Coupling constants, *J*, were reported in hertz unit (Hz). 13C NMR was recorded on Bruker Avance 400 MHz (100 MHz)and was fully decoupled by broad band proton decoupling. Chemical shifts were reported in ppm referenced to the center of a triplet at 77.0 ppm of chloroform-*d*. High resolution mass spectra were obtained on Waters Q– Tof Permier Spectrometer. Palladium acetate (98%) was purchased from Strem Chemicals Co., Ltd. Other reagents or catalysts were directly used from purchased without further purification unless otherwise specified.


II. General Procedure for the Preparation of Starting Materials

II-1. Mesityl(2,2,2-trifluoroethyl)iodonium trifluoromethanesulfonate (2)

2 was prepared following the procedure of previous literature.¹

II-2. Preparation of arene substrates

II-2-1. Procedure for the synthesis of N-methyl benzamides²



MeNH₂ methanol solution (33.3%) (1.5 equiv.), acid chloride (1.0 equiv.), Et₃N (2.0 equiv.) and Et₂O (0.5 M) were added into a round bottom flask capped with a septum. The mixture was stirred at room temperature. After 1 h, the crude reaction mixture was extracted with Et₂O, purified by flash chromatography to get the corresponding N-methyl benzamides.

II-2-2. Preparation of additional arene substrates

¹ Toth, L. B.; Kovacs, S.; Salyi, G.; Novak Z. Angew. Chem. Int. Ed. 2016, 55, 1988–1992; Angew. Chem. **2016**, 128, 2028–2032


² Tang, Q.; Xia, D.; Jin, X.; Zhang, Q.; Sun, Q. X.; Wang, C. J. Am. Chem. Soc., **2013**, 135, 4628–4631

Methyl benzoyl-*L*-phenylalaninate,³ methyl benzoyl-*L*-leucinate,⁴ and other benzamides were prepared according to the previously reported synthetic methods.

III. Optimization of reaction conditions

III-1. Solvent Effect

A 4 mL screw-cap vial equipped with a stirring bar was charged with *palladium(II) acetate* (0.007 mmol, 10 mol%, 1.6 mg), *N-methylbenzamide* (0.07 mmol, 10.0 mg) and *mesityl*(2,2,2-*trifluoroethyl)iodonium trifluoromethanesulfonate* (0.08 mmol, 42.4 mg). 0.5 mL *solvent* was added and the dark brown mixture was stirred at room temperature. T*rifluoroacetic acid* (0.05 mmol, 3.8 μ l) was added instantly and the vessel was capped for 24 hours. After that reaction conversion was initially checked by TLC. The solvent was then removed under vacuum and the crude was dissolved in CDCl₃ solvent and NMR was run for the sample to calculate the percentage of conversion.




Entry	Solvent	Yield	
1	МеОН	0	
2	CH ₃ CN	0	
3	Acetone	0	
4	THF	20	
5	DMF	0	
6	DMSO	0	
7	EtOAc	50	
8	Et ₂ O	90	
9	Toluene	45	
10	DCM	93	
11	DCE	96	

³ Thalhammer, A.; Mecinović, J.; Schofield, J. C. Tetrahedron Lett. 2009, 31, 1045-1047.

⁴ Das, S.; Li, Y.; Lu, Q. L.; Junge, K.; Beller, M. Chem. Eur. J. 2016, 22, 7050-7053.

III-2. Screening of catalysts

A 4 mL screw-cap vial equipped with a stirring bar was charged with *metal catalyst* (0.007 mmol, 10 mol%), *N-methylbenamide* (0.07 mmol, 10.0 mg) and *mesityl*(2,2,2-*trifluoroethyl)iodonium trifluoromethanesulfonate* (0.08 mmol, 42.4 mg). 0.5 mL *1*, 2-*dichloroethane* was added and the dark brown mixture was stirred at room temperature. T*rifluoroacetic acid* (0.05 mmol, 3.8 μ l) was added instantly and the vessel was capped for 24 hours. After that reaction conversion was initially checked by TLC. Then the solvent was removed under vaccum and the crude was dissolved in CDCl₃ solvent and NMR was run for the sample to calculate the percentage of conversion.



III-3. Effect of Acid additives


A 4 mL screw-cap vial equipped with a stirring bar was charged with *palladium(II) acetate* (0.007 mmol, 10 mol%, 1.6 mg), *N-methylbenamide* (0.07 mmol, 10.0 mg) and *mesityl*(2,2,2-*trifluoroethyl)iodonium trifluoromethanesulfonate* (0.08 mmol, 42.4 mg). 0.5 mL 1, 2-*dichloroethane* was added and the dark brown mixture was stirred at room temperature. Acid additive (0.05 mmol, 3.8 μ I) was added instantly and the vessel was capped for 24 hours. After

that reaction conversion was initially checked by TLC. Then the solvent was removed under vaccum and the crude was dissolved in $CDCl_3$ solvent and NMR was run for the sample to calculate the percentage of conversion.

Me - NH	+ Me + Me Me	CF ₃ Acid (1 0.5 ml	· · · ·	Me NH
	Entry	Acid	Yield	
	1	No acid	25	•
	2	H_2SO_4	56	
	3	HBF ₄	92	
	4	АсОН	15	
	5	TfOH	28	
	6	TsOH. H ₂ O	88	
	7	BF ₃ .OEt	91]

III-4. Catalyst Loading


A 4 mL screw-cap vial equipped with a stirring bar was charged with *palladium(II) acetate* (x mol%), *N-methylbenamide* (0.07 mmol, 10.0 mg) and *mesityl*(2,2,2-*trifluoroethyl)iodonium trifluoromethanesulfonate* (0.08 mmol, 42.4 mg). 0.5 mL *1*, 2-*dichloroethane* was added and the dark brown mixture was stirred at room temperature. T*rifluoroacetic acid* (0.05 mmol, 3.8 μ l) was added instantly and the vessel was capped for 24 hours. After that reaction conversion was initially checked by TLC. Then the solvent was removed under vaccum and the crude was dissolved in CDCl₃ solvent and NMR was run for the sample to calculate the percentage of conversion.



	3	7.5	67
4	4	10.0	96


IV Experimental Procedure for Pd-Catalyzed C-H Trifluoroethylation of Arenes and Spectroscopic Data of Compounds Obtained in this Study

IV-1 Palladium catalyzed direct C-C bond formation of N-methyl aromatic amides with 1 (Table 1)




A 4 mL screw-cap vial equipped with a stirring bar was charged with *palladium(II) acetate* (0.1 mmol, 10 mol%), *N-methylbenzamide* (1, 1 mmol) and *mesityl(2,2,2-trifluoroethyl)iodonium trifluoromethanesulfonate* (2,1.2 mmol). 0.5 mL *DCE* was added and the dark brown mixture was stirred at room temperature. Trifluoroacetic acid (1 mmol) was added instantly and the vessel was capped for 24 hours. After the completion, the reaction mixture was washed with NaHCO₃ solution and extracted with EtOAc (3 x 20mL). The combined organics were dried over MgSO₄, filtered and dried under vacuum to get the crude product, which was further purified by flash column chromatography using EtOAc and Hexane solvent system to furnish the desired product **3**.

N-methyl-2-(2,2,2-trifluoroethyl)benzamide (3a)




Following the general procedure, **3a** was obtained as a white solid (42 mg, 0.193 mmol, 96%). **MP** =168-169 °C ¹**H NMR** (400 MHz, CDCl₃) δ = 7.47 – 7.33 (m, 4H), 6.00 (s, 1H), 3.80 (q, *J*=11.0 Hz, 2H), 2.98 (d, *J*=4.9 Hz, 3H). ¹⁹**F NMR** (376 MHz, CDCl₃) δ = -65.33. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 170.16, 137.56, 132.26, 130.16, 128.76, 128.73, 128.20, 127.28, 127.11, 124.53, 36.66, 36.37, 36.07, 35.78, 26.68.**HRMS** (ESI): m/z calculated for C₁₀H₁₀F₃NO [M+H]⁺: 218.0793, found: 218.0804.

N,2-dimethyl-6-(2,2,2-trifluoroethyl)benzamide (3b)




Following the general procedure, **3b** was obtained as a white solid (34 mg, 0.147 mmol, 70%). **MP** =126-127 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.26 (t, *J*=7.6 Hz, 1H), 7.18 (t, *J*=6.8 Hz, 2H), 5.80 (s, 1H), 3.44 (q, *J*=10.9 Hz, 2H), 3.01 (d, *J*=4.9 Hz, 3H), 2.34 (s, 3H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -64.99. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 169.97, 138.90, 134.93, 130.11, 128.99, 128.42, 127.15, 126.82, 126.79, 126.47, 124.40, 37.51, 37.21, 36.91, 36.62, 26.39, 19.44. **HRMS** (ESI): m/z calculated for C₁₁H₁₂F₃NO [M+H]⁺: 232.0949, found: 232.0960.

2-chloro-*N*-methyl-6-(2,2,2-trifluoroethyl)benzamide (3c)



Following the general procedure **3c** was obtained as a white yellow solid (25 mg, 0.099 mmol, 52%). **MP** =108-109 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.41 – 7.24 (m, 3H), 5.85 (s, 1H), 3.51 (q, *J*=10.6 Hz, 2H), 3.03 (d, *J*=4.9 Hz, 3H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -64.99. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 166.91, 137.94, 131.31, 130.17, 129.69, 129.67, 129.62, 129.53, 129.29, 126.81, 124.06, 37.51, 37.21, 36.91, 36.61, 26.57. **HRMS** (ESI): m/z calculated for C₁₀H₉ClF₃NO [M+H]⁺: 252.0403, found: 252.0411.


N,5-dimethyl-2-(2,2,2-trifluoroethyl)benzamide (3d) and *N*,3-dimethyl-2-(2,2,2-trifluoroethyl)benzamide (3d')



Following the general procedure, **3d and 3d'** were obtained as inseparable mixture as white solid (40 mg, 0.173 mmol, 82%, **3d**: **3d'** = 5:1). **MP** =196-197 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.30 – 7.18 (m, 4H), 5.87 (s, 1H), 3.73 (q, *J*=11.0 Hz, 2H), 2.98 (d, *J*=4.9 Hz, 3H), 2.35 (s, 3H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -64.37. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 170.29,


138.17, 137.46, 137.43, 132.15, 130.83, 127.79, 120.00, 36.29, 36.01, 35.70, 35.44, 26.69, 20.98. **HRMS** (ESI): m/z calculated for C₁₁H₁₂F₃NO [M+H]⁺: 232.0949, found: 232.0941.

5-methoxy-*N*-methyl-2-(2,2,2-trifluoroethyl)benzamide (3e) and 3-methoxy-*N*-methyl-2-(2,2,2-trifluoroethyl)benzamide (3e')




Following the general procedure, **3e and 3e'** were obtained as inseparable mixture as white solid (34.3 mg, 0.138 mmol, 77%, **3e**: **3e'** = 5:1). **MP** = 165-166 °C.¹**H NMR** (400 MHz, CDCl₃) δ = 7.27 (dd, *J*=7.9, 4.2 Hz, 1H), 6.96 – 6.90 (m, 2H), 5.96 (s, 1H), 3.81 (s, 3H), 3.67 (q, *J*=11.0 Hz, 2H), 2.96 (d, *J*=4.9 Hz, 3H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -64.92. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 169.93, 159.21, 138.67, 133.42, 129.29, 127.38, 124.65, 120.40, 120.37, 119.04, 115.25, 113.09, 112.52, 55.44, 35.97, 35.67, 35.38, 35.08, 26.67. **HRMS** (ESI): m/z calculated for C₁₁H₁₂F₃NO₂ [M+H]⁺: 248.0898, found: 248.0894.

5-chloro-*N*-methyl-2-(2,2,2-trifluoroethyl)benzamide (3f) and 3-chloro-*N*-methyl-2-(2,2,2-trifluoroethyl)benzamide (3f')




Following the general procedure, **3f** and **3f'** were obtained as white solid (25 mg, 0.099 mmol, 56%). *Major* **3f MP** = 175-176 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.54 (dd, *J*=6.9, 2.5 Hz, 1H), 7.37 – 7.30 (m, 2H), 5.91 (s, 1H), 4.15 (q, *J*=10.7 Hz, 2H), 3.02 (d, *J*=4.9 Hz, 3H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -64.45.¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 169.53, 139.78, 137.42, 131.51, 129.32, 127.22, 127.17, 125.55, 124.41, 33.08, 32.77, 32.47, 32.17, 26.79. **HRMS** (ESI): m/z calculated for C₁₀H₉ClF₃NO [M+H]⁺: 252.0403, found: 252.0414. *Minor* **3f'** (7.4 mg, 0.029 mmol, 16.5% **MP** = 170-171 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.45 – 7.39 (m, 2H), 7.33 (d, *J*=8.1 Hz, 1H), 5.94 (s, 1H), 3.77 (q, *J*=10.9 Hz, 2H), 3.01 (d, *J*=4.9, 3H). ¹⁹**F NMR** (376 MHz, CDCl₃) δ = -65.42. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 168.66, 138.96, 134.30, 133.59, 130.24, 127.34, 127.31, 127.27, 124.24, 36.20, 35.90, 35.61, 35.31, 26.78. **HRMS** (ESI): m/z calculated for C₁₀H₉ClF₃NO [M+H]⁺: 252.0403, found: 252.0414.

N-methyl-2-(2,2,2-trifluoroethyl)-5-(trifluoromethyl)benzamide (3g)




Following the general procedure, **3g** was obtained as a white solid (28.6 mg, 0.100 mmol, 67%). **MP** = 177-178 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.69 (d, *J*=5.9 Hz, 2H), 7.52 (d, *J*=8.4 Hz, 1H), 5.99 (s, 1H), 3.85 (q, *J*=10.8 Hz, 2H), 3.01 (d, *J*=4.9 Hz, 3H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -62.89, -65.08. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 168.62, 138.24, 132.84, 130.87, 130.54, 126.86, 126.83, 124.77, 124.11, 124.07, 122.06, 36.66, 36.36, 36.06, 35.76, 26.82. **HRMS** (ESI): m/z calculated for C₁₁H₉F₆NO [M+H]⁺: 286.0667, found: 285.0667.

N,4-dimethyl-2-(2,2,2-trifluoroethyl)benzamide (3h)




Following the general procedure, **3h** was obtained as a white solid (51.7 mg, 0.223 mmol, 78%). **MP** =199-200 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.31 (d, *J*=7.7 Hz, 1H), 7.15 (d, *J*=10.6 Hz, 2H), 5.86 (s, 1H), 3.78 (q, *J*=11.0 Hz, 2H), 2.97 (d, *J*=4.9 Hz, 3H), 2.37 (s, 3H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -65.28. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 170.24, 140.40, 134.65, 133.02, 128.81, 127.36, 127.11, 124.60, 36.59, 36.30, 36.01, 35.71, 26.70, 21.21. **HRMS** (ESI): m/z calculated for C₁₁H₁₂F₃NO [M+H]⁺: 232.0949, found: 232.0955.

4-fluoro-N-methyl-2-(2,2,2-trifluoroethyl)benzamide (3i)




Following the general procedure, **3i** was obtained as a white solid (55 mg, 0.0.234 mmol, 68%). **MP** = 160-161 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.42 (dd, *J*=8.5, 5.7 Hz, 1H), 7.12 – 7.00 (m, 2H), 5.94 (s, 1H), 3.80 (q, *J*=10.8 Hz, 2H), 2.97 (d, *J*=4.9 Hz, 3H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -65.22, -109.54 - -109.60. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 169.23, 164.34, 161.85, 133.73, 133.70, 131.76, 131.68, 129.19, 129.10, 126.97, 124.21, 119.40, 119.18, 115.24, 115.03, 36.62, 36.33, 36.03, 35.73, 26.77. **HRMS** (ESI): m/z calculated for C₁₀H₉F₄NO [M+H]⁺: 236.0699, found: 236.0706.

4-chloro-*N*-methyl-2-(2,2,2-trifluoroethyl)benzamide (3j)




Following the general procedure, **3j** was obtained as a white solid (55 mg, 0.219 mmol, 75%). **MP** =168-169 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.40 – 7.30 (m, 4H), 5.93 (s, 1H), 3.77 (q, *J*=10.8 Hz, 2H), 2.97 (d, *J*=4.9 Hz, 3H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -65.20. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 169.13, 136.14, 135.86, 132.28, 130.87, 130.82, 128.43, 128.40, 126.95, 124.19, 36.48, 36.18, 35.88, 35.58, 26.77. **HRMS** (ESI): m/z calculated for C₁₀H₉ClF₃NO [M+H]⁺: 252.0403, found: 252.0403.

4-methoxy-*N*-methyl-2-(2,2,2-trifluoroethyl)benzamide (3k)




Following the general procedure, **3k** was obtained as a white solid (37.3 mg, 0.151 mmol, 84%). **MP.** =196-197 °C **¹H NMR** (400 MHz, CDCl₃) δ = 7.40 (d, *J*=8.4 Hz, 1H), 6.94 – 6.84 (m, 2H), 5.88 (s, 1H), 3.90 – 3.80 (m, 5H), 2.99 (d, *J*=4.9 Hz, 3H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -65.17. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 169.95, 160.65, 130.98, 130.95, 129.81, 128.73, 118.06, 113.00, 55.40, 36.75, 36.45, 36.16, 35.86, 26.74. **HRMS** (ESI): m/z calculated for C₁₁H₁₂F₃NO₂ [M+H]⁺: 248.0898, found: 248.0892.

N-methyl-2-(2,2,2-trifluoroethyl)-4-(trifluoromethyl)benzamide (3l)




Following the general procedure, **31** was obtained as a white solid (37.6 mg, 0.131 mmol, 74%). **MP** = 171-172 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.64 (d, *J*=6.3 Hz, 2H), 7.55 (d, *J*=8.4 Hz, 1H), 5.95 (s, 1H), 3.83 (q, *J*=10.8 Hz, 2H), 3.01 (d, *J*=4.9 Hz, 3H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -63.06, -65.28. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 168.76, 140.83, 132.80, 132.48, 132.15, 131.82, 129.91, 129.88, 129.58, 129.05, 129.01, 127.62, 126.83, 125.34, 125.31, 125.27, 125.23, 124.66, 124.07, 121.95, 36.68, 36.38, 36.08, 35.78, 26.81. **HRMS** (ESI): m/z calculated for C₁₁H₉F₆NO [M+H]⁺: 286.0667, found: 286.0667.

N-methyl-4-nitro-2-(2,2,2-trifluoroethyl)benzamide (3m)




Following the general procedure, **3m** was obtained as a white solid (28.0 mg, 0.106 mmol, 65%). **MP** =225-226 °C. ¹**H NMR** (400 MHz, DMSO) $\delta = 8.70$ (d, *J*=4.2 Hz, 1H), 8.37 (d, *J*=1.9 Hz, 1H), 8.30 (dd, *J*=8.4 Hz, 2.4, 1H), 7.74 (d, *J*=8.4 Hz, 1H), 4.12 (q, *J*=11.4 Hz, 2H), 2.79 (d, *J*=4.5 Hz, 3H). ¹⁹**F NMR** (376 MHz, DMSO) $\delta = -63.84$. ¹³**C NMR** (101 MHz, ¹⁹F coupled, DMSO) $\delta = 167.71$, 148.18, 143.86, 143.80, 130.91, 130.88, 129.97, 127.72, 127.13, 124.96, 123.73, 35.52, 35.23, 34.94, 34.65, 26.54. **HRMS** (ESI): m/z calculated for C₁₀H₉F₃N₂O₃ [M+H]⁺: 263.0644, found: 263.0641.

N-methyl-3-(2,2,2-trifluoroethyl)-[1, 1'-biphenyl]-4-carboxamide (3n)




Following the general procedure, **3n** was obtained as a white solid (48 mg, 0.163 mmol, 82%). **MP** =230-231 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.57 (dt, *J*=4.8, 1.6 Hz, 4H), 7.47 (t, *J*=11.5 Hz, 3H), 7.42 – 7.36 (m, 1H), 5.95 (s, 1H), 3.88 (q, *J*=11.0 Hz, 2H), 3.01 (d, *J*=4.9 Hz, 3H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -65.19. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 169.95, 143.21, 139.60, 136.14, 131.09, 129.47, 129.43, 129.42, 129.37, 128.97, 128.11, 127.64, 127.32, 127.19, 126.83, 124.57, 53.41, 36.83, 36.53, 36.24, 35.94, 26.77. **HRMS** (ESI): m/z calculated for C₁₆H₁₄F₃NO [M+H]⁺: 294.1106, found: 294.1115.

3, 5-difluoro-*N*-methyl-2-(2,2,2-trifluoroethyl)benzamide (30)




Following the general procedure, **30** was obtained as a white solid (46.3 mg, 0.183 mmol, 65%). **MP** =159-160 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.01 – 6.90 (m, 2H), 6.17 (s, 1H), 3.84 (q, *J*=10.6 Hz, 2H), 2.97 (d, *J*=4.8 Hz, 3H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -65.70, -65.73, -65.75, -65.78, -108.09 - -108.65. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 167.77, 163.56, 163.44, 161.06, 160.94, 140.43, 140.35, 126.79, 124.04, 112.93, 112.76, 110.71, 110.67, 110.48, 110.45, 105.89, 105.64, 105.62, 105.37, 29.11, 29.08, 28.80, 28.76, 28.48, 28.45, 28.17, 28.14, 26.74. **HRMS** (ESI): m/z calculated for C₁₀H₈F₅NO [M+H]⁺: 254.0604, found: 254.0608.

4, 5-dichloro-*N*-methyl-2-(2,2,2-trifluoroethyl)benzamide (3p)




Following the general procedure, **3p** was obtained as a white solid (31 mg, 0.108 mmol, 67%). **MP** =216-217 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.53 (s, 1H), 7.47 (s, 1H), 5.89 (s, 1H), 3.75 (q, *J*=10.7 Hz, 2H), 2.99 (d, *J*=4.9 Hz, 3H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -65.28. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 167.79, 136.98, 134.49, 134.03, 132.68, 129.07, 128.98, 128.88, 36.05, 35.75, 35.45, 35.15, 26.84. **HRMS** (ESI): m/z calculated for C₁₀H₈Cl₂F₃NO [M+H]⁺: 286.0013, found: 286.0011.

4, 5-dimethoxy-N-methyl-2-(2,2,2-trifluoroethyl)benzamide (3q)




Following the general procedure, **3q** was obtained as a white solid (38.1 mg, 0.137 mmol, 79%). **MP** =208-209 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 6.91 (s, 1H), 6.81 (s, 1H), 5.92 (s, 1H), 3.89 (d, *J*=10.0 Hz, 6H), 3.72 (q, *J*=10.9 Hz, 2H), 2.97 (d, *J*=4.7 Hz, 3H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -65.40. ¹³**C NMR** (101 MHz, ¹⁹**F** coupled, CDCl₃) δ = 169.89, 150.08, 148.47, 130.03, 127.38, 124.58, 121.54, 114.65, 110.47, 56.09, 56.05, 36.35, 36.06, 35.76, 35.47, 26.74. **HRMS** (ESI): m/z calculated for $C_{12}H_{14}F_3NO_3$ [M+H]⁺: 278.1004, found: 278.1003.

N-methyl-2-(2,2,2-trifluoroethyl)-1-naphthamide (3r)




Following the general procedure, **3r** was obtained as a white solid (31.8 mg, 0.119 mmol, 67%). **MP** =160-161 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.89 (ddd, *J*=15.8, 7.9, 1.5 Hz, 2H), 7.54 – 7.45 (m, 3H), 7.42 (d, *J*=8.0 Hz, 1H), 6.21 (s, 1H), 4.01 (dd, *J*=21.2, 10.5 Hz, 2H), 3.05 (d, *J*=4.9 Hz, 3H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -64.58. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 173.11, 135.12, 134.31, 132.16, 131.54, 130.01, 128.75, 127.65, 127.32, 126.24, 126.21, 125.81, 124.89, 124.49, 38.35, 38.06, 37.77, 37.48, 27.00. **HRMS** (ESI): m/z calculated for C₁₄H₁₂F₃NO [M+H]⁺: 268.0949, found: 268.0949

N-methyl-3-(2,2,2-trifluoroethyl)-2-naphthamide (3s)



Following the general procedure, **3s** was obtained as a white solid (34.8 mg, 0.130 mmol, 75%). **MP** =217-218 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.96 (s, 1H), 7.87 (d, *J*=7.6 Hz, 3H), 7.63 – 7.54 (m, 2H), 6.08 (s, 1H), 4.00 (q, *J*=11.0 Hz, 2H), 3.08 (d, *J*=4.9 Hz, 3H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -65.36. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 170.26, 134.96, 133.57, 132.06, 132.01, 127.89, 127.74, 127.71, 127.26, 127.12, 125.81, 125.77, 125.71, 125.68, 36.86, 36.57, 36.27, 35.95, 26.84.**HRMS** (ESI): m/z calculated for C₁₄H₁₂F₃NO [M+H]⁺: 268.0949, found: 268.0952

N-methyl-3-(2,2,2-trifluoroethyl)thiophene-2-carboxamide (3t)




Following the general procedure, **3t** was obtained as a white solid (18 mg, 0.080 mmol, 20%). **MP** =147-148 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.32 (d, *J*=5.1 Hz, 1H), 7.09 (d, *J*=5.0 Hz, 1H),

5.91 (s, 1H), 3.97 (q, *J*=10.9 Hz, 2H), 2.97 (d, *J*=4.9 Hz, 3H). ¹⁹**F** NMR (377 MHz, CDCl₃) δ = -65.00. ¹³**C** NMR (101 MHz, ¹⁹F coupled, CDCl₃) δ = 162.95, 134.00, 133.96, 133.59, 130.98, 126.96, 126.08, 124.21, 33.35, 33.05, 32.74, 32.44, 26.75. **HRMS** (ESI): m/z calculated for C₈H₈F₃NOS [M+H]⁺: 224.0357, found: 224.0366.


IV-2 Palladium catalyzed direct C-C bond formation of aromatic amides with 1 (Table 2)

N-ethyl-2-(2,2,2-trifluoroethyl)benzamide (5a)




Following the general procedure, **5a** was obtained as a white solid (42.8 mg, 0.185 mmol, 76%). **MP** =142-143 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.45 – 7.30 (m, 4H), 5.98 (s, 1H), 3.78 (q, *J*=11.0 Hz, 2H), 3.44 (qd, *J*=7.3, 5.9 Hz, 2H), 1.21 (t, *J*=7.3 Hz, 3H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = --65.25. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 169.40, 137.79, 132.24, 130.07, 128.66, 128.63, 128.19, 127.32, 127.09, 124.57, 36.64, 36.34, 36.04, 35.75, 34.82, 14.67. **HRMS** (ESI): m/z calculated for C₁₁H₁₂F₃NO [M+H]⁺: 232.0949, found: 232.0952.

N-benzyl-2-(2,2,2-trifluoroethyl)benzamide (5b)




Following the general procedure, **5b** was obtained as a white solid (21.5 mg, 0.073 mmol, 52%). **MP** =146-147 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.47 – 7.27 (m, 9H), 6.20 (s, 1H), 4.60 (d, *J*=5.7 Hz, 2H), 3.82 (q, *J*=11.0 Hz, 2H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -65.17. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 169.21, 137.79, 137.28, 132.38, 130.33, 128.97, 128.94, 128.84, 128.25, 127.91, 127.74, 127.29, 127.15, 44.12, 36.64, 36.34, 36.05, 35.75. **HRMS** (ESI): m/z calculated for C₁₆H₁₄F₃NO [M+H]⁺: 294.1106, found: 294.1112

N-propyl-2-(2,2,2-trifluoroethyl)benzamide (5c)




Following the general procedure, **5c** was obtained as a white solid (41.5 mg, 0.169 mmol, 80%). **MP** =130-131 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.45 – 7.30 (m, 4H), 5.99 (s, 1H), 3.78 (q, *J*=11.0 Hz, 2H), 3.41 – 3.34 (m, 2H), 1.68 – 1.55 (m, 2H), 0.97 (t, *J*=7.4 Hz, 3H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -65.24. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 169.49, 137.87, 132.24, 130.08, 128.69, 128.66, 128.19, 127.31, 127.09, 124.55, 41.69, 36.64, 36.34, 36.05, 35.75, 22.75, 11.31. **HRMS** (ESI): m/z calculated for C₁₂H₁₄F₃NO [M+H]⁺: 246.1106, found: 246.1112

N-butyl-2-(2,2,2-trifluoroethyl)benzamide (5d)




Following the general procedure, **5d** was obtained as a white solid (32.6 mg, 0.125 mmol, 72%). **MP** =127-129 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.45 – 7.31 (m, 4H), 5.95 (s, 1H), 3.78 (q, *J*=11.0 Hz, 2H), 3.41 (dd, *J*=13.1, 7.0 Hz, 2H), 1.62 – 1.53 (m, 2H), 1.40 (dq, *J*=14.4, 7.3 Hz, 2H), 0.95 (t, *J*=7.3 Hz, 3H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -65.24. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 169.44, 137.87, 132.23, 130.07, 128.69, 128.66, 128.19, 127.31, 127.09, 124.55, 39.70, 36.64, 36.35, 36.05, 35.76, 31.53, 20.05, 13.69. **HRMS** (ESI): m/z calculated for C₁₃H₁₆F₃NO [M+H]⁺: 260.1262, found: 260.1273

N-(tert-butyl)-2-(2,2,2-trifluoroethyl)benzamide (5f)




Following the general procedure, **5f** was obtained as a white solid (41.5 mg, 0.160 mmol, 85%). **MP** =117-118 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.43 – 7.29 (m, 4H), 5.71 (s, 1H), 3.76 (q, *J*=11.0 Hz, 2H), 1.45 (s, 9H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -65.12. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 169.02, 138.89, 132.19, 129.78, 128.28, 128.25, 128.15, 127.36, 127.03, 124.61, 52.00, 36.57, 36.27, 35.97, 35.68, 28.65. **HRMS** (ESI): m/z calculated for C₁₃H₁₆F₃NO [M+H]⁺: 260.1262, found: 260.1253

N-cyclopentyl-2-(2,2,2-trifluoroethyl)benzamide (5g)




Following the general procedure, **5g** was obtained as a white solid (33.1 mg, 0.122mmol, 73%). **MP** =154-155 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.44 – 7.32 (m, 4H), 5.86 (s, 1H), 4.44 – 4.30 (m, 1H), 3.77 (q, *J*=11.0 Hz, 2H), 2.12 – 2.01 (m, 2H), 1.75 – 1.60 (m, 4H), 1.48 (tt, *J*=13.1, 4.0 Hz, 2H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -65.20. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 169.10, 137.97, 132.24, 130.02, 128.57, 128.54, 127.33, 127.10, 124.58, 51.67, 36.66, 36.36, 36.07, 35.77, 33.03, 23.70. **HRMS** (ESI): m/z calculated for C₁₄H₁₆F₃NO [M+H]⁺: 272.1262, found: 272.1275

N-cyclohexyl-2-(2,2,2-trifluoroethyl)benzamide (5h)




Following the general procedure, **5h** was obtained as a white solid (35.4 mg, 0.124 mmol, 78%). **MP** =189-190 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.47 – 7.34 (m, 4H), 5.79 (d, *J*=6.6 Hz, 1H), 4.03 – 3.92 (m, 1H), 3.80 (q, *J*=11.0 Hz, 2H), 2.10 – 2.00 (m, 2H), 1.82 – 1.73 (m, 2H), 1.66 (dd, *J*=9.2, 5.3 Hz, 1H), 1.53 – 1.39 (m, 2H), 1.23 (tdd, *J*=16.8, 7.6, 4.1 Hz, 3H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -65.14. ¹³**C NMR** (101 MHz, ¹⁹**F** coupled, CDCl₃) δ = 168.62, 138.09, 132.24, 130.00, 128.55, 128.52, 128.21, 127.33, 127.08, 126.81, 124.58, 48.68, 36.67, 36.38, 36.08, 35.79, 32.99, 25.51, 24.83. **HRMS** (ESI): m/z calculated for $C_{15}H_{18}F_3NO$ [M+H]⁺: 286.1419, found: 286.1416.

N-(4-methoxybenzyl)-2-(2,2,2-trifluoroethyl)benzamide (5i)




Following the general procedure, **5i** was obtained as a white solid (33.0 mg, 0.102 mmol, 64%). **MP** =141-142 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.44 – 7.31 (m, 4H), 7.29 – 7.24 (m, 2H), 6.88 (d, *J*=8.6 Hz, 2H), 6.13 (s, 1H), 4.54 (d, *J*=5.6 Hz, 2H), 3.90 – 3.72 (m, 5H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -65.17. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 169.12, 159.22, 137.37, 132.35, 130.27, 129.86, 129.28, 128.92, 128.89, 128.23, 127.30, 127.14, 124.57, 114.22, 55.32, 43.60, 36.64, 36.35, 36.05, 35.76. **HRMS** (ESI): m/z calculated for C₁₇H₁₆F₃NO [M+H]⁺: 324.1211, found: 324.1213

N-((3s, 5s, 7s)-adamantan-1-yl)-2-(2,2,2-trifluoroethyl)benzamide (5j)




Following the general procedure, **5j** was obtained as a white solid (36.0 mg, 0.106mmol, 88%). **MP** =184-185 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.42 – 7.31 (m, 4H), 6.89 – 6.85 (m, 1H), 5.54 (s, 1H), 3.76 (q, *J*=11.0 Hz, 2H), 2.43 (s, 2H), 2.12 (d, *J*=7.5 Hz, 9H), 1.72 (s, 6H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -64.96. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 168.76, 141.75, 138.99, 137.32, 132.16, 129.74, 129.21, 128.30, 128.27, 128.24, 128.14, 127.94, 127.40, 127.03, 124.64, 52.76, 41.51, 36.60, 36.35, 36.30, 35.97, 35.71, 29.48. **HRMS** (ESI): m/z calculated for C₁₉H₂₂F₃NO [M+H]⁺: 338.1732, found: 338.1716.

(S)-N-(phenylethyl)-2-(2,2,2-trifluoroethyl)benzamide (5k)




Following the general procedure, **5k** was obtained as a white solid (26.0 mg, 0.084 mmol, 46%). **MP** =160-161 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.45 – 7.26 (m, 9H), 6.14 (d, *J*=6.9 Hz, 1H), 5.35 – 5.24 (m, 1H), 3.87 (dq, *J*=14.8, 11.0 Hz, 1H), 3.67 (dq, *J*=14.8, 11.0 Hz, 1H), 1.58 (d, *J*=6.9 Hz, 3H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -65.13. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 168.48, 142.73, 137.56, 132.32, 130.22, 128.79, 128.23, 127.57, 127.30, 127.14, 126.22, 124.55, 49.28, 36.60, 36.31, 36.01, 35.71, 21.46. **HRMS** (ESI): m/z calculated for C₁₇H₁₆F₃NO [M+H]⁺: 308.1262, found: 308.1273. ee = 96%. HPLC with an AS-H column at 254 nm (2-propanol: hexane = 10:90), 1.0 mL/min; major enantiomer t_{major}= 11.49 min, minoe enantiomer t_{minor}= 14.38 min.

Methyl (2-(2,2,2-trifluoroethyl)benzoyl)-D-leucinate (51)



Following the general procedure, **51** was obtained as a white solid (36.0 mg, 0.108 mmol, 74%). **MP** =125-126 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.44 (ddd, *J*=18.0, 14.4, 4.8 Hz, 4H), 6.26 (d, *J*=7.7 Hz, 1H), 4.81 (dd, *J*=10.2, 7.2 Hz, 1H), 3.96 – 3.65 (m, 5H), 1.81 – 1.57 (m, 3H), 0.98 (dd, *J*=8.9, 5.6 Hz, 6H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -65.19. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 173.23, 169.00, 136.93, 132.27, 130.48, 128.92, 128.90, 128.87, 128.29, 127.41, 127.25, 124.49, 52.37, 51.09, 41.48, 36.55, 36.26, 35.96, 35.67, 24.93, 22.80, 21.83. **HRMS** (ESI): m/z calculated for C₁₇H₁₆F₃NO [M+H]⁺: 332.1474, found: 332.1466. ee = 95%. HPLC with an AS-H column at 254 nm (2-propanol: hexane = 10:90), 1.0 mL/min; major enantiomer t_{major}= 6.32 min, minoe enantiomer t_{minor}= 9.18 min.


Methyl (2-(2,2,2-trifluoroethyl)benzoyl)-D-phenylalaninate (5m)




Following the general procedure, **5m** was obtained as a white solid (28.4 mg, 0.077 mmol, 65%). **MP** =155-156 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.49 – 7.25 (m, 7H), 7.19 (d, *J*=5.2 Hz, 2H), 6.35 (s, 1H), 5.16 – 5.05 (m, 1H), 3.82 (t, *J*=9.0 Hz, 5H), 3.27 (ddd, *J*=19.2, 13.8, 8.3 Hz, 2H). ¹⁹**F NMR** (377 MHz, CDCl₃) δ = -65.28. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CDCl₃) δ = 171.79, 168.68, 136.56, 135.74, 132.27, 130.56, 129.23, 129.05, 128.70, 128.29, 127.42, 127.27, 127.01, 124.47, 53.41, 52.47, 37.93, 36.50, 36.21, 35.91, 35.62. **HRMS** (ESI): m/z calculated for C₁₇H₁₆F₃NO [M+H]⁺: 366.1317, found: 366.1312. ee = 99%. HPLC with an AS-H column at 254 nm (2-propanol: hexane = 10:90), 1.0 mL/min; major enantiomer t_{major}= 11.81 min.

V. Mechanistic Studies


V-1. Deuterium labeling test




To a screw cap vial equipped with a stirbar were added *N*-methylbenzamide (**1a**, 15 mg, 0.1 mmol), *N*-methylbenzamide (1**a**-**D**₅, 15 mg, 0.1 mmol), mesityl(2,2,2-trifluoroethyl)iodonium trifluoromethanesulfonate (**2**, 127 mg, 0.24mmol), Pd(OAc)₂ (5.0 mg, 0.01 mmol, 10 mol %) and 1,2-dichloroethane (1.0 mL) under atmospheric conditions. Trifluoroacetic acid (0.1 mmol) was added instantly and the vessel was capped for 4 hours. After reaction mixture was washed with NaHCO₃ solution and extracted with EtOAc (3 x 20mL). Organic solvents were removed under reduced pressure and the residue was purified by chromatography on silica gel (*n*-hexane/EtOAc) to obtain the desired products with recovery of starting materials.




V-2 Procedure for the synthesis of Palladacycle compound





To a 15ml sealed-tube were added N-((3s,5s,7s)adamantan-1-yl)benzamide (50 mg, 0.20 mmol), Pd(OAc)₂ (44mg, 0.20 mmol) and 1ml TFA. The tube was sealed and stirred at rt for 24h. Then the reaction mixture was filtered and washed with hexane to give the desired TFA bridged palladacycle product **6** as a yellowish green solid (78 mg, 82%). The yellowish green solid was then recrystallized from hexane/DCE to give crystal that can be characterized by X-ray crystallography. **MP** = °C. ¹**H NMR** (400 MHz, CD₂Cl₂) δ = 7.15 (s, 2H), 6.97 (s, 1H), 6.71 (d, *J*=34.4 Hz, 1H), 6.34 (s, 1H), 5.09 (s, 2H), 2.13 (s, 9H), 1.70 (s, 6H). ¹⁹**F NMR** (377 MHz, CD₂Cl₂) δ = -73.88, -74.26, -74.35, -74.83, -76.08. ¹³**C NMR** (101 MHz, ¹⁹F coupled, CD₂Cl₂) δ = 179.11, 143.96, 140.64, 131.93, 131.05, 130.97, 130.86, 130.81, 125.03, 124.33, 54.82, 41.08, 35.97, 29.54.





A 4 mL screw-cap vial equipped with a stirring bar was charged with *palladacycle* compound (6, 20.0 mg, 0.2 mmol) and *mesityl*(2,2,2-*trifluoroethyl*)*iodonium trifluoromethanesulfonate* (2, 0.22 mmol). Then 0.5 mL *DCE* was added and started to stir the dark brown mixture at room temperature. After the completion of the reaction, Reaction mixture was washed with NaHCO₃ solution and extracted with EtOAc (3 x 20mL). The combined organics were dried over MgSO₄, filtered and dried under vacuum to get the crude product, which was further purified by flash column chromatography using EtOAc and Hexane solvent system to furnish desired product **5j** in 80% yield.






















10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 -11(ppm)





















 $\leftarrow^{-65,25}_{-65,31}$














10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 f1 (ppm)










































10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 f1 (ppm)


























































10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 f1 (ppm)




ManiCF3_MeBenzylamine90% Hex AS-H 1ml_min 60min 23Mar201




PDA Chl 254nm 4nm													
Peak#	Ret. Time	Area	Height	Area %	Height %								
1	11.497	99271	4759	97.771	97.689								
2	14.381	2263	113	2.229	2.311								
Total		101535	4872	100.000	100.000								







ManiCF3_NPhalaninate90% Hex AS-H 1ml_min 30min 23Mar2017




Total








ManiCF3_NMeLeucinate90% Hex AS-H 1ml_min 60min 23Mar2017



				Peaklable											
1	PDA Ch1 254nm 4nm														
	Peak#	Ret. Time	Area	Height	Area %	Height %									
	1	6.324	120938	8543	97.201	97.736									
	2	9.181	3483	198	2.799	2.264									
	Total		124421	8741	100.000	100.000									







												, , ,					_,		· · · · ·
190	180	170	160	150	140	130	120	110	100 f1 (ppm)	90	8	30	70	60	50	40		30	20